渤健公司 BIIB 深 沪
等待开盘 10-06 09:30:00 美东时间
223.59
+3.710
+1.69%
华盛通- 最 高230.49
- 今 开219.90
- 成交量 91.21万股
- 最 低 208.9279
- 昨 收 219.88
- 总市值 3264.41万
- 52周最高 230.49
- 市盈率 静 21.50
- 换手率 624.69%
- 52周最低 138.00
- 委 比 -55.64%
- 总股本 0.00亿
- 历史最高 468.55
- 量 比 0.65
- 振 幅 9.81%
- 历史最低 0.00
- 每 手 1
- 风险率 20.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment Leqembi
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment
07-14 02:23
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.
07-13 19:07
Biogen: Key Takeaways From Needham’s Meeting With Top Management
Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key priorities. PT increased to $256.
06-29 23:27
Needham Maintains Buy on Biogen, Raises Price Target to $256
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.
06-29 18:08
This House of Representative Just Bought Up To $375K In Biogen Stock
Records from June 8, 2026 indicate that Representative Maria Elvira Salazar of ...
06-09 23:15
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and other stock views.
06-08 21:58
UCB and Biogen Report Late-Stage Lupus Trial Results for Experimental Drug
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial
06-01 16:40
Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
Evercore ISI Group Reinstates Outperform on Biogen
Evercore ISI Group analyst Umer Raffat reinstates Biogen (NASDAQ:BIIB) with a Outperform.
05-16 01:48
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
FDA extends review for Biogen's Leqembi Iqlik for early Alzheimer's disease to August 2026.
05-08 23:31
